Title: Spotlight Commentary: Deprescribing in long-term care facilities – Towards Safer and Smarter Medication Use in Older AdultsAuthors: Nataša Skočibušić 1,2,3, Igor Rubinić1,2, Vera Vlahović-Palčevski 1,2Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Krešimirova 42, 51000Faculty of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, CroatiaDepartment of Health Ecology, Teaching Institute of Public Health of Primorsko-goranska, County, Krešimirova 52a, 51000 Rijeka, CroatiaCorresponding author : Nataša SkočibušićWord count : 1060References : 10 (BJCP: 6)Potentially inappropriate medication (PIM) use remains highly prevalent among older adults in long-term care facilities (LTCF), despite its well-documented risks for adverse clinical, functional, and economic outcomes. Numerous strategies have been explored to optimize pharmacotherapy in this vulnerable population, yet identifying interventions that reliably improve prescribing quality and resident outcomes remains an ongoing challenge. Evidence supporting broad, system-level interventions to enhance prescribing practice in long-term care is still limited, despite smaller-scale studies demonstrating meaningful benefits for residents’ health and well-being.The British Journal of Clinical Pharmacology has published several key contributions addressing these concerns, including research on PIMs, deprescribing initiatives, and pharmacist-led interventions to improve medication management in older adults. These studies underscore the complexity of medication optimization in aged care, highlighting the need for adaptable, evidence-based strategies that consider clinical context, patient-specific factors, and healthcare system variability.The global population of older adults is expanding at an unprecedented rate, with projections indicating that by 2050, approximately 17% of the world’s population, around 1.6 billion people, will be aged 65 and older 1. As life expectancy rises, the prevalence of polypharmacy, the concurrent use of multiple medications, has increased significantly. Polypharmacy increases the likelihood of exposure to PIMs, encompassing suboptimal prescribing practices such as overprescribing, underprescribing, and misprescribing, which are strongly linked to negative outcomes including reduced quality of life, hospitalizations, adverse drug reactions (ADRs), falls, disability, and mortality 2. Older adults often face multimorbidity, frailty, cognitive decline, and social deprivation, factors that not only complicate pharmacotherapy but also challenge the delivery of integrated care within predominantly disease-centered medical systems.A particularly vulnerable subgroup comprises older adults in LTCF, where adverse outcomes from inappropriate medication use are highly prevalent. Roller-Wirnsberger et al. highlighted that multimorbidity, defined as the coexistence of multiple chronic diseases without a single dominant condition, affects over 60% of individuals aged 65 years and older and increases with advancing age 3. Managing such patients often extends beyond standard clinical protocols, requiring more personalized and holistic models of care.A recent systematic review by Gutteridge et al. reinforced the critical importance of effective medication management in nursing homes and other long-term care settings 4. The authors identified medication-related harm as a global health priority, particularly in aged care services, where polypharmacy and complex treatment regimens are common. Their review underscored the need for comprehensive medication management systems, continuous quality monitoring, and multidisciplinary engagement. Pharmacist-led medication reviews, deprescribing initiatives, and ongoing staff education, emerge as key components in improving medication safety and optimizing therapeutic outcomes.Certain medication classes, such as benzodiazepines, Z-drugs, antidepressants, antithrombotic agents, opioids, antipsychotics, diuretics, insulin, and anticonvulsants, are particularly associated with ADRs in this population 5. These are frequently associated with adverse effects such as falls, haemorrhagic events, constipation, delirium, and hypoglycaemia – common causes of emergency department visits and hospitalizations 5. Despite recognition of these issues, PIM prescribing remains widespread in LTCF, posing ongoing clinical, economic, and ethical challenges.A study by Roberts et al., involving 52 nursing homes, demonstrated that pharmacist-led interventions implemented in collaboration with nursing and medical staff significantly improved medication appropriateness and reduced psychoactive and unnecessary drug use among nursing home residents 6. Subsequently, Cool et al. confirmed the benefits of multidisciplinary strategy, demonstrating that a general geriatric intervention, centred on staff education and support, reduced PIM use 7. Structural and organizational factors, including special care units and access to psychiatric services, also shaped prescribing patterns. Although reductions in high-risk medications, such as long half-life benzodiazepines, were modest, the findings reinforced the value of a coordinated, team-based approaches to medication optimisation.Building on these multidisciplinary and educational strategies, deprescribing has emerged as a central approach to reducing medication-related harm in older adults. Deprescribing refers to the systematic, supervised discontinuation of medications that are no longer necessary or may cause harm. It is particularly relevant in frail older adults who are more susceptible to ADRs due to age-related pharmacokinetics and pharmacodynamics changes, multimorbidity, and functional decline. The goal extends beyond simply reducing medication burden and involves aligning therapy with current clinical needs, life expectancy, and patient preferences. Effective deprescribing involves comprehensive medication review, careful evaluation of risks and benefits, shared decision-making with patients and caregivers, and close monitoring for withdrawal effects or symptom recurrence8,9.Evidence from nursing home populations demonstrates that such interventions, led by pharmacists working alongside physicians and nurses, can reduce PIM prevalence in nursing homes by up to 59%, while simultaneously lowering all-cause mortality by 26% and falls by 24%, without increasing hospitalizations or withdrawal-related adverse events8. Key elements of success include prioritization of high-risk drug classes, patient and caregiver education, ongoing monitoring, and using validated tools such as the Beers Criteria or STOPP/START to guide medication review. Shared decision-making enhances patient satisfaction and adherence, although its direct impact on clinical endpoints remains less clear 8.A systematic review by Page et al. confirmed that deprescribing interventions are generally safe and feasible 9. While randomized trials showed no significant change in mortality, non-randomized studies suggested potential survival benefits, particularly in those aged 65–80 years. Outcomes varied by medication type, e.g. discontinuing bisphosphonates was typically safe due to their prolonged effects, whereas withdrawal of antihypertensives produced modest blood pressure increases requiring individualized management. These findings affirm that selected medications can often be safely withdrawn without compromising health outcomes or quality of life.While most attention was focused on prescribed medications, the contribution of over-the-counter (OTC) drugs represent an often-overlooked source of medication-related harm in older adults. Commonly used agents such as non-opioid analgesics, antacids, laxatives, and cough or cold preparations are frequently self-administered, often perceived as harmless, and rarely disclosed to clinicians. However, they can contribute to therapy duplication, drug-drug interactions, and ADRs10. Incorporating OTC medication use into comprehensive medication reviews is therefore essential for safe prescribing practices.In conclusion, polypharmacy and inappropriate prescribing remain critical challenges in the care of older adults, particularly those in long-term care settings. Deprescribing offers a pragmatic, evidence-based strategy to optimize medication use, reduce harm, and improve clinical outcomes. Its success depends on structured, multidisciplinary, patient-centred approaches that employ validated assessment tools and shared decision-making. Continued research is needed to improve deprescribing processes, clarify long-term impact, and develop scalable models adaptable across diverse healthcare settings. By advancing ad disseminating such evidence, BJCP continues to play an important role in promoting safe, rational, person-centred pharmacotherapy for the world’s growing older population.